Clinical Trials Logo

Acquired Hemophilia A clinical trials

View clinical trials related to Acquired Hemophilia A.

Filter by:
  • None
  • Page 1

NCT ID: NCT04580407 Not yet recruiting - Clinical trials for Acquired Hemophilia A

Study of TAK-672 in Participants With Acquired Hemophilia A

Start date: March 12, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

The main aims of the study are to learn if TAK-672 can control bleeds in participants with acquired hemophilia A and if the participants have side effects from TAK-672. Acquired hemophilia A is when people's immune system attacks specific proteins, known as clotting factors, in their bodies. This is different from hemophilia A, which is a condition people are born with. At the first visit, the study doctor will check who can take part. For those who can take part, participants will visit the clinic or hospital when they get their next bleed. They will receive TAK-672 slowly through a vein. This is called an infusion. They might need extra infusions of TAK-672 to control the bleed. After their bleed is controlled, participants will regularly visit the clinic for a check-up and to treat any further bleeds. This will happen until all participants have received their last dose of TAK-672 to control their 1st bleed. After this, all participants will visit the clinic 90 days later for a final check-up.

NCT ID: NCT03700229 Recruiting - Clinical trials for Acquired Hemophilia A

Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A

Start date: October 10, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this prospective study is to determine the efficacy and safety of Rituximab plus Bortezomib in patients with newly diagnosed acquired hemophilia A.

NCT ID: NCT03384277 Recruiting - Clinical trials for Acquired Hemophilia A

Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab

Start date: October 26, 2017
Phase: Phase 3
Study type: Interventional

Purpose: To evaluate the efficacy when administering steroid combined with single dose rituximab to eliminate the antibody in acquired hemophilia A patients compared to treatment using steroid with cyclophosphamide. The study will test the hypothesis that steroid combined with small dose rituximab is as effective as steroid combined with cyclophosphamide for FVIII inhibitor eradication in Chinese patients with acquired hemophilia A. Study design Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment

NCT ID: NCT03199794 Recruiting - Clinical trials for Acquired Hemophilia A

Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice

Start date: December 14, 2016
Phase:
Study type: Observational

The study addresses the safety, utilisation and effectiveness of Obizur in the treatment of bleeding episodes in real-life clinical practice in Europe and the United States.

NCT ID: NCT02610127 Completed - Clinical trials for Acquired Hemophilia A

Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A

Start date: December 30, 2015
Phase:
Study type: Observational

The overall objective is to enroll patients with acquired hemophilia A (AHA) who are prescribed and treated with Obizur, to assess safety, and to describe factors related to safety, utilization and effectiveness in a real-world setting.

NCT ID: NCT01968655 No longer available - Clinical trials for Acquired Hemophilia A

Expanded Access to B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies

Start date: n/a
Phase: N/A
Study type: Expanded Access

To provide emergency access to OBI-1 for patients with Acquired Hemophilia and a serious bleeding episode who do not have access to an active clinical study site associated with the OBI-1-301 study.

NCT ID: NCT01178294 Completed - Clinical trials for Acquired Hemophilia A

Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A

Start date: November 10, 2010
Phase: Phase 2/Phase 3
Study type: Interventional

This study is to test whether the study drug (OBI-1) is safe and effective for the treatment of serious bleeding episodes in people with acquired hemophilia A.